



March 29, 2023

Attention: Certain U.S. Shareholders of ProQR Therapeutics N.V.

Re: ProQR Therapeutics N.V. and its subsidiaries PFIC Annual Information Statement

Because ProQR Therapeutics N.V. (the "Company") and its subsidiaries are Dutch corporations and have passive income and passive assets, it is possible that the Company and its subsidiaries meet the definition of a passive foreign investment company ("PFIC") under Section 1297 of the Internal Revenue Code of 1986, as amended (the "Code") for their 2022 taxable years. Certain U.S. income tax consequences flow from this designation and these consequences may be mitigated by the U.S. shareholder electing to treat the foreign corporations as "qualified electing funds" ("QEFs") under Section 1295 of the Code.

Since it is possible that the Company and its subsidiaries may be PFICs for their 2022 taxable years, the Company and its subsidiaries are providing the attached PFIC Annual Information Statements pursuant to the requirements of Treasury Regulation 1.1295-1(g)(1). The PFIC Annual Information Statements contain information to enable you or your tax advisor to prepare your tax return if you elect to treat the Company and its subsidiaries as QEFs.

A U.S. shareholder who makes a QEF election is required to annually include in one's income one's pro rata share of the ordinary earnings and net capital gains for the Company. The QEF election is made by attaching IRS Form 8621 to your federal income tax return filed by the due date of the return, as extended.

WE RECOMMEND U.S. SHAREHOLDERS CONSULT WITH THEIR TAX ADVISORS REGARDING ANY DECISION TO MAKE (OR REFRAIN FROM MAKING) ANY ELECTION THAT MAY BE AVAILABLE TO THEM BECAUSE ANY SUCH DECISION WILL DEPEND UPON THEIR OWN PARTICULAR TAX SITUATION AND MAY HAVE SIGNIFICANT AND CONTINUING U.S. TAX CONSEQUENCES. THE COMPANY IS UNABLE TO GIVE ADVICE IN THIS REGARD.



PROQR THERAPEUTICS N.V.

PASSIVE FOREIGN INVESTMENT COMPANY (“PFIC”) 2022 ANNUAL INFORMATION STATEMENT

The Information Statement is provided for shareholders who are United States persons. In order to assist you in preparation of Form 8621, we provide the following information:

1. Pursuant to United States Treasury Regulation Section 1.1295-1(g)(1), ProQR Therapeutics N.V. (the “Company”) hereby represents that, to the best of its knowledge,
 - a. This information statement applies to the taxable year of ProQR Therapeutics N.V. beginning on January 1, 2022 and ending on December 31, 2022 (the “Taxable Year”).
 - b. Each shareholder of the Company has a pro-rata share of the ordinary earnings and net capital gain, as defined in Treasury Regulation Section 1.1293-1(a)(2), of the Company for the Taxable Year specified in paragraph 1a as follows:

Ordinary Earnings: \$-0-
Net Capital Gain: \$-0-

Based on weighted-average shares outstanding of 71,641,305, the pro-rata share of the ordinary earnings and net capital gain per share, as defined in Treasury Regulation Section 1.1293-1(a)(2), of the Company for the Taxable Year specified in paragraph 1a as follows:

Ordinary Earnings: \$-0-/share
Net Capital Gain: \$-0-/share

- c. The amount of cash and fair market value of other property distributed or deemed distributed by the Company to each shareholder of the Company during the Taxable Year specified in paragraph 1a as follows:

Cash: \$-0-
Fair Market Value of Property: \$-0-

2. The Company will permit its shareholders to inspect and copy the Company’s permanent books of account, records, and such other documents as may be maintained by the Company that are necessary to establish that PFIC ordinary earnings and net capital gain, as provided in section 1293(e) of the Internal Revenue Code, are computed in accordance with U.S. federal



income tax principles, and to verify these amounts and the shareholder's pro rata shares thereof.

/s/

Jurriaan Dekkers
CFO

ProQR Therapeutics N.V.
Zernikedreef 9
2333 CK Leiden
The Netherlands
Date: March 29, 2023

THIS INFORMATION IS PROVIDED IN ORDER TO ASSIST THOSE SHAREHOLDERS WHO HAVE MADE A QEF ELECTION WITH RESPECT TO PROQR THERAPEUTICS N.V. IN MAKING CERTAIN PFIC CALCULATIONS AND DOES NOT CONSTITUTE TAX ADVICE. THOSE SHAREHOLDERS ARE ADVISED TO CONSULT THEIR OWN TAX ADVISORS CONCERNING THE OVERALL TAX CONSEQUENCES OF THE OWNERSHIP OF SHARES ARISING IN THEIR OWN PARTICULAR SITUATIONS UNDER UNITED STATES FEDERAL, STATE, LOCAL AND FOREIGN LAW.



PROQR THERAPEUTICS HOLDING B.V.

PASSIVE FOREIGN INVESTMENT COMPANY (“PFIC”) 2022 ANNUAL INFORMATION STATEMENT

The Information Statement is provided for shareholders who are United States persons. In order to assist you in preparation of Form 8621, we provide the following information:

1. Pursuant to United States Treasury Regulation Section 1.1295-1(g)(1), ProQR Therapeutics Holding B.V. (the “Company”) hereby represents that, to the best of its knowledge,
 - a. This information statement applies to the taxable year of ProQR Therapeutics Holding B.V. beginning on January 1, 2022 and ending on December 31, 2022 (the “Taxable Year”).
 - b. Each shareholder of the Company has a pro-rata share of the ordinary earnings and net capital gain, as defined in Treasury Regulation Section 1.1293-1(a)(2), of the Company for the Taxable Year specified in paragraph 1a as follows:

Ordinary Earnings: \$-0-
Net Capital Gain: \$-0-

Based on weighted-average shares outstanding of 71,641,305, the pro-rata share of the ordinary earnings and net capital gain per share, as defined in Treasury Regulation Section 1.1293-1(a)(2), of the Company for the Taxable Year specified in paragraph 1a as follows:

Ordinary Earnings: \$-0-/share
Net Capital Gain: \$-0-/share

- c. The amount of cash and fair market value of other property distributed or deemed distributed by the Company to each shareholder of the Company during the Taxable Year specified in paragraph 1a as follows:

Cash: \$-0-
Fair Market Value of Property: \$-0-

2. The Company will permit its shareholders to inspect and copy the Company’s permanent books of account, records, and such other documents as may be maintained by the Company that are necessary to establish that PFIC ordinary earnings and net capital gain, as provided in section 1293(e) of the Internal Revenue Code, are computed in accordance with U.S. federal



income tax principles, and to verify these amounts and the shareholder's pro rata shares thereof.

/s/

Jurriaan Dekkers
CFO

ProQR Therapeutics Holding B.V.
Zernikedreef 9
2333 CK Leiden
The Netherlands
Date: March 29, 2023

THIS INFORMATION IS PROVIDED IN ORDER TO ASSIST THOSE SHAREHOLDERS WHO HAVE MADE A QEF ELECTION WITH RESPECT TO PROQR THERAPEUTICS HOLDING B.V. IN MAKING CERTAIN PFIC CALCULATIONS AND DOES NOT CONSTITUTE TAX ADVICE. THOSE SHAREHOLDERS ARE ADVISED TO CONSULT THEIR OWN TAX ADVISORS CONCERNING THE OVERALL TAX CONSEQUENCES OF THE OWNERSHIP OF SHARES ARISING IN THEIR OWN PARTICULAR SITUATIONS UNDER UNITED STATES FEDERAL, STATE, LOCAL AND FOREIGN LAW.



PROQR THERAPEUTICS I B.V.

PASSIVE FOREIGN INVESTMENT COMPANY (“PFIC”) 2022 ANNUAL INFORMATION STATEMENT

The Information Statement is provided for shareholders who are United States persons. In order to assist you in preparation of Form 8621, we provide the following information:

1. Pursuant to United States Treasury Regulation Section 1.1295-1(g)(1), ProQR Therapeutics I B.V. (the “Company”) hereby represents that, to the best of its knowledge,
 - a. This information statement applies to the taxable year of ProQR Therapeutics I B.V. beginning on January 1, 2022 and ending on December 31, 2022 (the “Taxable Year”).
 - b. Each shareholder of the Company has a pro-rata share of the ordinary earnings and net capital gain, as defined in Treasury Regulation Section 1.1293-1(a)(2), of the Company for the Taxable Year specified in paragraph 1a as follows:

Ordinary Earnings: \$-0-
Net Capital Gain: \$-0-

Based on weighted-average shares outstanding of 71,641,305, the pro-rata share of the ordinary earnings and net capital gain per share, as defined in Treasury Regulation Section 1.1293-1(a)(2), of the Company for the Taxable Year specified in paragraph 1a as follows:

Ordinary Earnings: \$-0-/share
Net Capital Gain: \$-0-/share

- c. The amount of cash and fair market value of other property distributed or deemed distributed by the Company to each shareholder of the Company during the Taxable Year specified in paragraph 1a as follows:

Cash: \$-0-
Fair Market Value of Property: \$-0-
2. The Company will permit its shareholders to inspect and copy the Company’s permanent books of account, records, and such other documents as may be maintained by the Company that are necessary to establish that PFIC ordinary earnings and net capital gain, as provided in section 1293(e) of the Internal Revenue Code, are computed in accordance with U.S. federal



income tax principles, and to verify these amounts and the shareholder's pro rata shares thereof.

/s/

Jurriaan Dekkers
CFO

ProQR Therapeutics I B.V.
Zernikedreef 9
2333 CK Leiden
The Netherlands
Date: March 29, 2023

THIS INFORMATION IS PROVIDED IN ORDER TO ASSIST THOSE SHAREHOLDERS WHO HAVE MADE A QEF ELECTION WITH RESPECT TO PROQR THERAPEUTICS I B.V. IN MAKING CERTAIN PFIC CALCULATIONS AND DOES NOT CONSTITUTE TAX ADVICE. THOSE SHAREHOLDERS ARE ADVISED TO CONSULT THEIR OWN TAX ADVISORS CONCERNING THE OVERALL TAX CONSEQUENCES OF THE OWNERSHIP OF SHARES ARISING IN THEIR OWN PARTICULAR SITUATIONS UNDER UNITED STATES FEDERAL, STATE, LOCAL AND FOREIGN LAW.



PROQR THERAPEUTICS II B.V.

PASSIVE FOREIGN INVESTMENT COMPANY (“PFIC”) 2022 ANNUAL INFORMATION STATEMENT

The Information Statement is provided for shareholders who are United States persons. In order to assist you in preparation of Form 8621, we provide the following information:

3. 1. Pursuant to United States Treasury Regulation Section 1.1295-1(g)(1), ProQR Therapeutics II B.V. (the “Company”) hereby represents that, to the best of its knowledge,
 - a. This information statement applies to the taxable year of ProQR Therapeutics II B.V. beginning on January 1, 2022 and ending on December 31, 2022 (the “Taxable Year”).
 - b. Each shareholder of the Company has a pro-rata share of the ordinary earnings and net capital gain, as defined in Treasury Regulation Section 1.1293-1(a)(2), of the Company for the Taxable Year specified in paragraph 1a as follows:

Ordinary Earnings: \$-0-
Net Capital Gain: \$-0-

Based on weighted-average shares outstanding of 71,641,305, the pro-rata share of the ordinary earnings and net capital gain per share, as defined in Treasury Regulation Section 1.1293-1(a)(2), of the Company for the Taxable Year specified in paragraph 1a as follows:

Ordinary Earnings: \$-0-/share
Net Capital Gain: \$-0-/share

- c. The amount of cash and fair market value of other property distributed or deemed distributed by the Company to each shareholder of the Company during the Taxable Year specified in paragraph 1a as follows:

Cash: \$-0-
Fair Market Value of Property: \$-0-

4. The Company will permit its shareholders to inspect and copy the Company’s permanent books of account, records, and such other documents as may be maintained by the Company that are necessary to establish that PFIC ordinary earnings and net capital gain, as provided in section 1293(e) of the Internal Revenue Code, are computed in accordance with U.S. federal



income tax principles, and to verify these amounts and the shareholder's pro rata shares thereof.

/s/

Jurriaan Dekkers
CFO

ProQR Therapeutics II B.V.
Zernikedreef 9
2333 CK Leiden
The Netherlands
Date: March 29, 2023

THIS INFORMATION IS PROVIDED IN ORDER TO ASSIST THOSE SHAREHOLDERS WHO HAVE MADE A QEF ELECTION WITH RESPECT TO PROQR THERAPEUTICS II B.V. IN MAKING CERTAIN PFIC CALCULATIONS AND DOES NOT CONSTITUTE TAX ADVICE. THOSE SHAREHOLDERS ARE ADVISED TO CONSULT THEIR OWN TAX ADVISORS CONCERNING THE OVERALL TAX CONSEQUENCES OF THE OWNERSHIP OF SHARES ARISING IN THEIR OWN PARTICULAR SITUATIONS UNDER UNITED STATES FEDERAL, STATE, LOCAL AND FOREIGN LAW.



PROQR THERAPEUTICS III B.V.

PASSIVE FOREIGN INVESTMENT COMPANY (“PFIC”) 2022 ANNUAL INFORMATION STATEMENT

The Information Statement is provided for shareholders who are United States persons. In order to assist you in preparation of Form 8621, we provide the following information:

1. Pursuant to United States Treasury Regulation Section 1.1295-1(g)(1), ProQR Therapeutics III B.V. (the “Company”) hereby represents that, to the best of its knowledge,
 - a. This information statement applies to the taxable year of ProQR Therapeutics III B.V. beginning on January 1, 2022 and ending on December 31, 2022 (the “Taxable Year”).
 - b. Each shareholder of the Company has a pro-rata share of the ordinary earnings and net capital gain, as defined in Treasury Regulation Section 1.1293-1(a)(2), of the Company for the Taxable Year specified in paragraph 1a as follows:

Ordinary Earnings: \$-0-
Net Capital Gain: \$-0-

Based on weighted-average shares outstanding of 71,641,305, the pro-rata share of the ordinary earnings and net capital gain per share, as defined in Treasury Regulation Section 1.1293-1(a)(2), of the Company for the Taxable Year specified in paragraph 1a as follows:

Ordinary Earnings: \$-0-/share
Net Capital Gain: \$-0-/share

- c. The amount of cash and fair market value of other property distributed or deemed distributed by the Company to each shareholder of the Company during the Taxable Year specified in paragraph 1a as follows:

Cash: \$-0-
Fair Market Value of Property: \$-0-
2. The Company will permit its shareholders to inspect and copy the Company’s permanent books of account, records, and such other documents as may be maintained by the Company that are necessary to establish that PFIC ordinary earnings and net capital gain, as provided in section 1293(e) of the Internal Revenue Code, are computed in accordance with U.S. federal



income tax principles, and to verify these amounts and the shareholder's pro rata shares thereof.

/s/

Jurriaan Dekkers
CFO

ProQR Therapeutics III B.V.
Zernikedreef 9
2333 CK Leiden
The Netherlands
Date: March 29, 2023

THIS INFORMATION IS PROVIDED IN ORDER TO ASSIST THOSE SHAREHOLDERS WHO HAVE MADE A QEF ELECTION WITH RESPECT TO PROQR THERAPEUTICS III B.V. IN MAKING CERTAIN PFIC CALCULATIONS AND DOES NOT CONSTITUTE TAX ADVICE. THOSE SHAREHOLDERS ARE ADVISED TO CONSULT THEIR OWN TAX ADVISORS CONCERNING THE OVERALL TAX CONSEQUENCES OF THE OWNERSHIP OF SHARES ARISING IN THEIR OWN PARTICULAR SITUATIONS UNDER UNITED STATES FEDERAL, STATE, LOCAL AND FOREIGN LAW.



PROQR THERAPEUTICS IV B.V.

PASSIVE FOREIGN INVESTMENT COMPANY (“PFIC”) 2022 ANNUAL INFORMATION STATEMENT

The Information Statement is provided for shareholders who are United States persons. In order to assist you in preparation of Form 8621, we provide the following information:

1. Pursuant to United States Treasury Regulation Section 1.1295-1(g)(1), ProQR Therapeutics III B.V. (the “Company”) hereby represents that, to the best of its knowledge,
 - a. This information statement applies to the taxable year of ProQR Therapeutics IV B.V. beginning on January 1, 2022 and ending on December 31, 2022 (the “Taxable Year”).
 - b. Each shareholder of the Company has a pro-rata share of the ordinary earnings and net capital gain, as defined in Treasury Regulation Section 1.1293-1(a)(2), of the Company for the Taxable Year specified in paragraph 1a as follows:

Ordinary Earnings: \$-0-
Net Capital Gain: \$-0-

Based on weighted-average shares outstanding of 71,641,305, the pro-rata share of the ordinary earnings and net capital gain per share, as defined in Treasury Regulation Section 1.1293-1(a)(2), of the Company for the Taxable Year specified in paragraph 1a as follows:

Ordinary Earnings: \$-0-/share
Net Capital Gain: \$-0-/share

- c. The amount of cash and fair market value of other property distributed or deemed distributed by the Company to each shareholder of the Company during the Taxable Year specified in paragraph 1a as follows:

Cash: \$-0-
Fair Market Value of Property: \$-0-

2. The Company will permit its shareholders to inspect and copy the Company’s permanent books of account, records, and such other documents as may be maintained by the Company that are necessary to establish that PFIC ordinary earnings and net capital gain, as provided in section 1293(e) of the Internal Revenue Code, are computed in accordance with U.S. federal



income tax principles, and to verify these amounts and the shareholder's pro rata shares thereof.

/s/

Jurriaan Dekkers
CFO

ProQR Therapeutics IV B.V.
Zernikedreef 9
2333 CK Leiden
The Netherlands
Date: March 29, 2023

THIS INFORMATION IS PROVIDED IN ORDER TO ASSIST THOSE SHAREHOLDERS WHO HAVE MADE A QEF ELECTION WITH RESPECT TO PROQR THERAPEUTICS IV B.V. IN MAKING CERTAIN PFIC CALCULATIONS AND DOES NOT CONSTITUTE TAX ADVICE. THOSE SHAREHOLDERS ARE ADVISED TO CONSULT THEIR OWN TAX ADVISORS CONCERNING THE OVERALL TAX CONSEQUENCES OF THE OWNERSHIP OF SHARES ARISING IN THEIR OWN PARTICULAR SITUATIONS UNDER UNITED STATES FEDERAL, STATE, LOCAL AND FOREIGN LAW.



PROQR THERAPEUTICS V B.V.

PASSIVE FOREIGN INVESTMENT COMPANY (“PFIC”) 2022 ANNUAL INFORMATION STATEMENT

The Information Statement is provided for shareholders who are United States persons. In order to assist you in preparation of Form 8621, we provide the following information:

1. Pursuant to United States Treasury Regulation Section 1.1295-1(g)(1), ProQR Therapeutics III B.V. (the “Company”) hereby represents that, to the best of its knowledge,
 - a. This information statement applies to the taxable year of ProQR Therapeutics V B.V. beginning on January 1, 2022 and ending on December 31, 2022 (the “Taxable Year”).
 - b. Each shareholder of the Company has a pro-rata share of the ordinary earnings and net capital gain, as defined in Treasury Regulation Section 1.1293-1(a)(2), of the Company for the Taxable Year specified in paragraph 1a as follows:

Ordinary Earnings: \$-0-
Net Capital Gain: \$-0-

Based on weighted-average shares outstanding of 71,641,305, the pro-rata share of the ordinary earnings and net capital gain per share, as defined in Treasury Regulation Section 1.1293-1(a)(2), of the Company for the Taxable Year specified in paragraph 1a as follows:

Ordinary Earnings: \$-0-/share
Net Capital Gain: \$-0-/share

- c. The amount of cash and fair market value of other property distributed or deemed distributed by the Company to each shareholder of the Company during the Taxable Year specified in paragraph 1a as follows:

Cash: \$-0-
Fair Market Value of Property: \$-0-
2. The Company will permit its shareholders to inspect and copy the Company’s permanent books of account, records, and such other documents as may be maintained by the Company that are necessary to establish that PFIC ordinary earnings and net capital gain, as provided in section 1293(e) of the Internal Revenue Code, are computed in accordance with U.S. federal



income tax principles, and to verify these amounts and the shareholder's pro rata shares thereof.

/s/

Jurriaan Dekkers
CFO

ProQR Therapeutics V B.V.
Zernikedreef 9
2333 CK Leiden
The Netherlands
Date: March 29, 2023

THIS INFORMATION IS PROVIDED IN ORDER TO ASSIST THOSE SHAREHOLDERS WHO HAVE MADE A QEF ELECTION WITH RESPECT TO PROQR THERAPEUTICS V B.V. IN MAKING CERTAIN PFIC CALCULATIONS AND DOES NOT CONSTITUTE TAX ADVICE. THOSE SHAREHOLDERS ARE ADVISED TO CONSULT THEIR OWN TAX ADVISORS CONCERNING THE OVERALL TAX CONSEQUENCES OF THE OWNERSHIP OF SHARES ARISING IN THEIR OWN PARTICULAR SITUATIONS UNDER UNITED STATES FEDERAL, STATE, LOCAL AND FOREIGN LAW.



PROQR THERAPEUTICS VI B.V.

PASSIVE FOREIGN INVESTMENT COMPANY (“PFIC”) 2022 ANNUAL INFORMATION STATEMENT

The Information Statement is provided for shareholders who are United States persons. In order to assist you in preparation of Form 8621, we provide the following information:

1. Pursuant to United States Treasury Regulation Section 1.1295-1(g)(1), ProQR Therapeutics III B.V. (the “Company”) hereby represents that, to the best of its knowledge,
 - a. This information statement applies to the taxable year of ProQR Therapeutics VI B.V. beginning on January 1, 2022 and ending on December 31, 2022 (the “Taxable Year”).
 - b. Each shareholder of the Company has a pro-rata share of the ordinary earnings and net capital gain, as defined in Treasury Regulation Section 1.1293-1(a)(2), of the Company for the Taxable Year specified in paragraph 1a as follows:

Ordinary Earnings: \$-0-
Net Capital Gain: \$-0-

Based on weighted-average shares outstanding of 71,641,305, the pro-rata share of the ordinary earnings and net capital gain per share, as defined in Treasury Regulation Section 1.1293-1(a)(2), of the Company for the Taxable Year specified in paragraph 1a as follows:

Ordinary Earnings: \$-0-/share
Net Capital Gain: \$-0-/share

- c. The amount of cash and fair market value of other property distributed or deemed distributed by the Company to each shareholder of the Company during the Taxable Year specified in paragraph 1a as follows:

Cash: \$-0-
Fair Market Value of Property: \$-0-

2. The Company will permit its shareholders to inspect and copy the Company’s permanent books of account, records, and such other documents as may be maintained by the Company that are necessary to establish that PFIC ordinary earnings and net capital gain, as provided in section 1293(e) of the Internal Revenue Code, are computed in accordance with U.S. federal



income tax principles, and to verify these amounts and the shareholder's pro rata shares thereof.

/s/

Jurriaan Dekkers
CFO

ProQR Therapeutics VI B.V.
Zernikedreef 9
2333 CK Leiden
The Netherlands
Date: March 29, 2023

THIS INFORMATION IS PROVIDED IN ORDER TO ASSIST THOSE SHAREHOLDERS WHO HAVE MADE A QEF ELECTION WITH RESPECT TO PROQR THERAPEUTICS VI B.V. IN MAKING CERTAIN PFIC CALCULATIONS AND DOES NOT CONSTITUTE TAX ADVICE. THOSE SHAREHOLDERS ARE ADVISED TO CONSULT THEIR OWN TAX ADVISORS CONCERNING THE OVERALL TAX CONSEQUENCES OF THE OWNERSHIP OF SHARES ARISING IN THEIR OWN PARTICULAR SITUATIONS UNDER UNITED STATES FEDERAL, STATE, LOCAL AND FOREIGN LAW.



PROQR THERAPEUTICS VII B.V.

PASSIVE FOREIGN INVESTMENT COMPANY (“PFIC”) 2022 ANNUAL INFORMATION STATEMENT

The Information Statement is provided for shareholders who are United States persons. In order to assist you in preparation of Form 8621, we provide the following information:

1. Pursuant to United States Treasury Regulation Section 1.1295-1(g)(1), ProQR Therapeutics III B.V. (the “Company”) hereby represents that, to the best of its knowledge,
 - a. This information statement applies to the taxable year of ProQR Therapeutics VII B.V. beginning on January 1, 2022 and ending on December 31, 2022 (the “Taxable Year”).
 - b. Each shareholder of the Company has a pro-rata share of the ordinary earnings and net capital gain, as defined in Treasury Regulation Section 1.1293-1(a)(2), of the Company for the Taxable Year specified in paragraph 1a as follows:

Ordinary Earnings: \$-0-
Net Capital Gain: \$-0-

Based on weighted-average shares outstanding of 71,641,305, the pro-rata share of the ordinary earnings and net capital gain per share, as defined in Treasury Regulation Section 1.1293-1(a)(2), of the Company for the Taxable Year specified in paragraph 1a as follows:

Ordinary Earnings: \$-0-/share
Net Capital Gain: \$-0-/share

- c. The amount of cash and fair market value of other property distributed or deemed distributed by the Company to each shareholder of the Company during the Taxable Year specified in paragraph 1a as follows:

Cash: \$-0-
Fair Market Value of Property: \$-0-
2. The Company will permit its shareholders to inspect and copy the Company’s permanent books of account, records, and such other documents as may be maintained by the Company that are necessary to establish that PFIC ordinary earnings and net capital gain, as provided in section 1293(e) of the Internal Revenue Code, are computed in accordance with U.S. federal



income tax principles, and to verify these amounts and the shareholder's pro rata shares thereof.

/s/

Jurriaan Dekkers
CFO

ProQR Therapeutics VII B.V.
Zernikedreef 9
2333 CK Leiden
The Netherlands
Date: March 29, 2023

THIS INFORMATION IS PROVIDED IN ORDER TO ASSIST THOSE SHAREHOLDERS WHO HAVE MADE A QEF ELECTION WITH RESPECT TO PROQR THERAPEUTICS VII B.V. IN MAKING CERTAIN PFIC CALCULATIONS AND DOES NOT CONSTITUTE TAX ADVICE. THOSE SHAREHOLDERS ARE ADVISED TO CONSULT THEIR OWN TAX ADVISORS CONCERNING THE OVERALL TAX CONSEQUENCES OF THE OWNERSHIP OF SHARES ARISING IN THEIR OWN PARTICULAR SITUATIONS UNDER UNITED STATES FEDERAL, STATE, LOCAL AND FOREIGN LAW.



PROQR THERAPEUTICS VIII B.V.

PASSIVE FOREIGN INVESTMENT COMPANY (“PFIC”) 2022 ANNUAL INFORMATION STATEMENT

The Information Statement is provided for shareholders who are United States persons. In order to assist you in preparation of Form 8621, we provide the following information:

1. Pursuant to United States Treasury Regulation Section 1.1295-1(g)(1), ProQR Therapeutics III B.V. (the “Company”) hereby represents that, to the best of its knowledge,
 - a. This information statement applies to the taxable year of ProQR Therapeutics VIII B.V. beginning on January 1, 2022 and ending on December 31, 2022 (the “Taxable Year”).
 - b. Each shareholder of the Company has a pro-rata share of the ordinary earnings and net capital gain, as defined in Treasury Regulation Section 1.1293-1(a)(2), of the Company for the Taxable Year specified in paragraph 1a as follows:

Ordinary Earnings: \$-0-
Net Capital Gain: \$-0-

Based on weighted-average shares outstanding of 71,641,305, the pro-rata share of the ordinary earnings and net capital gain per share, as defined in Treasury Regulation Section 1.1293-1(a)(2), of the Company for the Taxable Year specified in paragraph 1a as follows:

Ordinary Earnings: \$-0-/share
Net Capital Gain: \$-0-/share

- c. The amount of cash and fair market value of other property distributed or deemed distributed by the Company to each shareholder of the Company during the Taxable Year specified in paragraph 1a as follows:

Cash: \$-0-
Fair Market Value of Property: \$-0-
2. The Company will permit its shareholders to inspect and copy the Company’s permanent books of account, records, and such other documents as may be maintained by the Company that are necessary to establish that PFIC ordinary earnings and net capital gain, as provided in section 1293(e) of the Internal Revenue Code, are computed in accordance with U.S. federal



income tax principles, and to verify these amounts and the shareholder's pro rata shares thereof.

/s/

Jurriaan Dekkers
CFO

ProQR Therapeutics VIII B.V.
Zernikedreef 9
2333 CK Leiden
The Netherlands
Date: March 29, 2023

THIS INFORMATION IS PROVIDED IN ORDER TO ASSIST THOSE SHAREHOLDERS WHO HAVE MADE A QEF ELECTION WITH RESPECT TO PROQR THERAPEUTICS VIII B.V. IN MAKING CERTAIN PFIC CALCULATIONS AND DOES NOT CONSTITUTE TAX ADVICE. THOSE SHAREHOLDERS ARE ADVISED TO CONSULT THEIR OWN TAX ADVISORS CONCERNING THE OVERALL TAX CONSEQUENCES OF THE OWNERSHIP OF SHARES ARISING IN THEIR OWN PARTICULAR SITUATIONS UNDER UNITED STATES FEDERAL, STATE, LOCAL AND FOREIGN LAW.



PROQR THERAPEUTICS IX B.V.

PASSIVE FOREIGN INVESTMENT COMPANY (“PFIC”) 2022 ANNUAL INFORMATION STATEMENT

The Information Statement is provided for shareholders who are United States persons. In order to assist you in preparation of Form 8621, we provide the following information:

1. Pursuant to United States Treasury Regulation Section 1.1295-1(g)(1), ProQR Therapeutics III B.V. (the “Company”) hereby represents that, to the best of its knowledge,
 - a. This information statement applies to the taxable year of ProQR Therapeutics IX B.V. beginning on January 1, 2022 and ending on December 31, 2022 (the “Taxable Year”).
 - b. Each shareholder of the Company has a pro-rata share of the ordinary earnings and net capital gain, as defined in Treasury Regulation Section 1.1293-1(a)(2), of the Company for the Taxable Year specified in paragraph 1a as follows:

Ordinary Earnings: \$-0-
Net Capital Gain: \$-0-

Based on weighted-average shares outstanding of 71,641,305, the pro-rata share of the ordinary earnings and net capital gain per share, as defined in Treasury Regulation Section 1.1293-1(a)(2), of the Company for the Taxable Year specified in paragraph 1a as follows:

Ordinary Earnings: \$-0-/share
Net Capital Gain: \$-0-/share

- c. The amount of cash and fair market value of other property distributed or deemed distributed by the Company to each shareholder of the Company during the Taxable Year specified in paragraph 1a as follows:

Cash: \$-0-
Fair Market Value of Property: \$-0-
2. The Company will permit its shareholders to inspect and copy the Company’s permanent books of account, records, and such other documents as may be maintained by the Company that are necessary to establish that PFIC ordinary earnings and net capital gain, as provided in section 1293(e) of the Internal Revenue Code, are computed in accordance with U.S. federal



income tax principles, and to verify these amounts and the shareholder's pro rata shares thereof.

/s/

Jurriaan Dekkers
CFO

ProQR Therapeutics IX B.V.
Zernikedreef 9
2333 CK Leiden
The Netherlands
Date: March 29, 2023

THIS INFORMATION IS PROVIDED IN ORDER TO ASSIST THOSE SHAREHOLDERS WHO HAVE MADE A QEF ELECTION WITH RESPECT TO PROQR THERAPEUTICS IX B.V. IN MAKING CERTAIN PFIC CALCULATIONS AND DOES NOT CONSTITUTE TAX ADVICE. THOSE SHAREHOLDERS ARE ADVISED TO CONSULT THEIR OWN TAX ADVISORS CONCERNING THE OVERALL TAX CONSEQUENCES OF THE OWNERSHIP OF SHARES ARISING IN THEIR OWN PARTICULAR SITUATIONS UNDER UNITED STATES FEDERAL, STATE, LOCAL AND FOREIGN LAW.



AMYLON THERAPEUTICS B.V.

PASSIVE FOREIGN INVESTMENT COMPANY (“PFIC”) 2022 ANNUAL INFORMATION STATEMENT

The Information Statement is provided for shareholders who are United States persons. In order to assist you in preparation of Form 8621, we provide the following information:

1. Pursuant to United States Treasury Regulation Section 1.1295-1(g)(1), Amylon Therapeutics B.V. (the “Company”) hereby represents that, to the best of its knowledge,
 - a. This information statement applies to the taxable year of Amylon Therapeutics B.V. beginning on January 1, 2022 and ending on December 31, 2022 (the “Taxable Year”).
 - b. Each shareholder of the Company has a pro-rata share of the ordinary earnings and net capital gain, as defined in Treasury Regulation Section 1.1293-1(a)(2), of the Company for the Taxable Year specified in paragraph 1a as follows:

Ordinary Earnings: \$-0-
Net Capital Gain: \$-0-

Based on weighted-average shares outstanding of 71,641,305, the pro-rata share of the ordinary earnings and net capital gain per share, as defined in Treasury Regulation Section 1.1293-1(a)(2), of the Company for the Taxable Year specified in paragraph 1a as follows:

Ordinary Earnings: \$-0-/share
Net Capital Gain: \$-0-/share

- c. The amount of cash and fair market value of other property distributed or deemed distributed by the Company to each shareholder of the Company during the Taxable Year specified in paragraph 1a as follows:

Cash: \$-0-
Fair Market Value of Property: \$-0-

2. The Company will permit its shareholders to inspect and copy the Company’s permanent books of account, records, and such other documents as may be maintained by the Company that are necessary to establish that PFIC ordinary earnings and net capital gain, as provided in section 1293(e) of the Internal Revenue Code, are computed in accordance with U.S. federal



income tax principles, and to verify these amounts and the shareholder's pro rata shares thereof.

/s/

Jurriaan Dekkers
CFO of ProQR group, parent company of Amylon Therapeutics B.V.

Amylon Therapeutics B.V.
Zernikedreef 9
2333 CK Leiden
The Netherlands
Date: March 29, 2023

THIS INFORMATION IS PROVIDED IN ORDER TO ASSIST THOSE SHAREHOLDERS WHO HAVE MADE A QEF ELECTION WITH RESPECT TO AMYLON THERAPEUTICS B.V. IN MAKING CERTAIN PFIC CALCULATIONS AND DOES NOT CONSTITUTE TAX ADVICE. THOSE SHAREHOLDERS ARE ADVISED TO CONSULT THEIR OWN TAX ADVISORS CONCERNING THE OVERALL TAX CONSEQUENCES OF THE OWNERSHIP OF SHARES ARISING IN THEIR OWN PARTICULAR SITUATIONS UNDER UNITED STATES FEDERAL, STATE, LOCAL AND FOREIGN LAW.